{
    "id": 28840,
    "fullName": "IGF2BP3 over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "IGF2BP3 over exp indicates an over expression of the Igf2bp3 protein and/or mRNA. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 10643,
        "geneSymbol": "IGF2BP3",
        "terms": [
            "IGF2BP3",
            "CT98",
            "IMP-3",
            "IMP3",
            "KOC",
            "KOC1",
            "VICKZ3"
        ]
    },
    "variant": "over exp",
    "createDate": "10/18/2018",
    "updateDate": "10/18/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 15065,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Linsitinib (OSI-906) inhibited migration, invasion, and growth of pancreatic cancer cells overexpressing Igf2bp3 in culture, and arrested tumor growth in cell line xenograft models (PMID: 28193878).",
            "molecularProfile": {
                "id": 30727,
                "profileName": "IGF2BP3 over exp"
            },
            "therapy": {
                "id": 798,
                "therapyName": "Linsitinib",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12604,
                    "pubMedId": 28193878,
                    "title": "THADA fusion is a mechanism of IGF2BP3 activation and IGF1R signaling in thyroid cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28193878"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15067,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Linsitinib (OSI-906) inhibited growth of osteosarcoma cells overexpressing Igf2bp3 in culture (PMID: 28193878).",
            "molecularProfile": {
                "id": 30727,
                "profileName": "IGF2BP3 over exp"
            },
            "therapy": {
                "id": 798,
                "therapyName": "Linsitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12604,
                    "pubMedId": 28193878,
                    "title": "THADA fusion is a mechanism of IGF2BP3 activation and IGF1R signaling in thyroid cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28193878"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15066,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Linsitinib (OSI-906) inhibited growth of thyroid cancer cells overexpressing Igf2bp3 in culture (PMID: 28193878).",
            "molecularProfile": {
                "id": 30727,
                "profileName": "IGF2BP3 over exp"
            },
            "therapy": {
                "id": 798,
                "therapyName": "Linsitinib",
                "synonyms": null
            },
            "indication": {
                "id": 1781,
                "name": "thyroid gland cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12604,
                    "pubMedId": 28193878,
                    "title": "THADA fusion is a mechanism of IGF2BP3 activation and IGF1R signaling in thyroid cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28193878"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15068,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Linsitinib (OSI-906) arrested tumor growth in cell line xenograft models of colon cancer overexpressing Igf2bp3 (PMID: 28193878).",
            "molecularProfile": {
                "id": 30727,
                "profileName": "IGF2BP3 over exp"
            },
            "therapy": {
                "id": 798,
                "therapyName": "Linsitinib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12604,
                    "pubMedId": 28193878,
                    "title": "THADA fusion is a mechanism of IGF2BP3 activation and IGF1R signaling in thyroid cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28193878"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 30727,
            "profileName": "IGF2BP3 over exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}